These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 17666312)
1. Differences of nine drug resistance interpretation systems in predicting short-term therapy outcomes of treatment-experienced HIV-1 infected patients: a retrospective observational cohort study. Helm M; Walter H; Ehret R; Schmit JC; Kurowski M; Knechten H; Korn K; Braun P; Schmidt B Eur J Med Res; 2007 Jun; 12(6):231-42. PubMed ID: 17666312 [TBL] [Abstract][Full Text] [Related]
2. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Van Laethem K; De Luca A; Antinori A; Cingolani A; Perna CF; Vandamme AM Antivir Ther; 2002 Jun; 7(2):123-9. PubMed ID: 12212924 [TBL] [Abstract][Full Text] [Related]
3. Construction, training and clinical validation of an interpretation system for genotypic HIV-1 drug resistance based on fuzzy rules revised by virological outcomes. De Luca A; Vendittelli M; Baldini F; Di Giambenedetto S; Trotta MP; Cingolani A; Bacarelli A; Gori C; Perno CF; Antinori A; Ulivi G Antivir Ther; 2004 Aug; 9(4):583-93. PubMed ID: 15456090 [TBL] [Abstract][Full Text] [Related]
4. Virologic therapy response significantly correlates with the number of active drugs as evaluated using a LiPA HIV-1 resistance scoring system. Ziermann R; Celis L; Derdelinckx I; Lambert C; Veeck J; Rizzo MG; Vanderborght B; Zissis G; Clumeck N; Fransen K; Vaira D; Hendricks D; Van Laethem K; Vandamme AM; Schmit JC; Knechten H; De Luca A; Louwagie J; Segers P; De Boeck K; Pottel H; De Brauwer A; Hulstaert F J Clin Virol; 2004 Dec; 31 Suppl 1():S7-15. PubMed ID: 15567089 [TBL] [Abstract][Full Text] [Related]
5. Rules-based HIV-1 genotypic resistance interpretation systems predict 8 week and 24 week virological antiretroviral treatment outcome and benefit from drug potency weighting. Zazzi M; Prosperi M; Vicenti I; Di Giambenedetto S; Callegaro A; Bruzzone B; Baldanti F; Gonnelli A; Boeri E; Paolini E; Rusconi S; Giacometti A; Maggiolo F; Menzo S; De Luca A; J Antimicrob Chemother; 2009 Sep; 64(3):616-24. PubMed ID: 19620134 [TBL] [Abstract][Full Text] [Related]
6. Variability in the interpretation of transmitted genotypic HIV-1 drug resistance and prediction of virological outcomes of the initial HAART by distinct systems. De Luca A; Cozzi-Lepri A; Perno CF; Balotta C; Di Giambenedetto S; Poggio A; Pagano G; Tositti G; Piscopo R; Del Forno A; Chiodo F; Magnani G; d'Arminio Monforte A; ; Antivir Ther; 2004 Oct; 9(5):743-52. PubMed ID: 15535412 [TBL] [Abstract][Full Text] [Related]
7. A comparison of three computational modelling methods for the prediction of virological response to combination HIV therapy. Wang D; Larder B; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; D'Arminio Monforte A; Torti C; Zazzi M; Lane C Artif Intell Med; 2009 Sep; 47(1):63-74. PubMed ID: 19524413 [TBL] [Abstract][Full Text] [Related]
8. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. Cozzi-Lepri A; Phillips AN; Clotet B; Mocroft A; Ruiz L; Kirk O; Lazzarin A; Wiercinska-Drapalo A; Karlsson A; Lundgren JD; AIDS; 2008 Oct; 22(16):2187-98. PubMed ID: 18832882 [TBL] [Abstract][Full Text] [Related]
9. Investigation of expert rule bases, logistic regression, and non-linear machine learning techniques for predicting response to antiretroviral treatment. Prosperi MC; Altmann A; Rosen-Zvi M; Aharoni E; Borgulya G; Bazso F; Sönnerborg A; Schülter E; Struck D; Ulivi G; Vandamme AM; Vercauteren J; Zazzi M; Antivir Ther; 2009; 14(3):433-42. PubMed ID: 19474477 [TBL] [Abstract][Full Text] [Related]
10. Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. Assoumou L; Brun-Vézinet F; Cozzi-Lepri A; Kuritzkes D; Phillips A; Zolopa A; Degruttola V; Miller V; Costagliola D; J Infect Dis; 2008 Aug; 198(4):470-80. PubMed ID: 18598191 [TBL] [Abstract][Full Text] [Related]
12. The development of artificial neural networks to predict virological response to combination HIV therapy. Larder B; Wang D; Revell A; Montaner J; Harrigan R; De Wolf F; Lange J; Wegner S; Ruiz L; Pérez-Elías MJ; Emery S; Gatell J; Monforte AD; Torti C; Zazzi M; Lane C Antivir Ther; 2007; 12(1):15-24. PubMed ID: 17503743 [TBL] [Abstract][Full Text] [Related]
13. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. Spudich S; Lollo N; Liegler T; Deeks SG; Price RW J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340 [TBL] [Abstract][Full Text] [Related]
14. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine. Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460 [TBL] [Abstract][Full Text] [Related]
15. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006. Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758 [TBL] [Abstract][Full Text] [Related]
16. Genotypic drug resistance and long-term mortality in patients with triple-class antiretroviral drug failure. Lohse N; Jørgensen LB; Kronborg G; Møller A; Kvinesdal B; Sørensen HT; Obel N; Gerstoft J; Antivir Ther; 2007; 12(6):909-17. PubMed ID: 17926645 [TBL] [Abstract][Full Text] [Related]
17. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. García-Gascó P; Maida I; Blanco F; Barreiro P; Martín-Carbonero L; Vispo E; González-Lahoz J; Soriano V J Antimicrob Chemother; 2008 Mar; 61(3):699-704. PubMed ID: 18192682 [TBL] [Abstract][Full Text] [Related]
18. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors. Fox ZV; Geretti AM; Kjaer J; Dragsted UB; Phillips AN; Gerstoft J; Staszewski S; Clotet B; von Wyl V; Lundgren JD AIDS; 2007 Oct; 21(15):2033-42. PubMed ID: 17885293 [TBL] [Abstract][Full Text] [Related]
19. Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. Di Giambenedetto S; Bracciale L; Colafigli M; Cattani P; Pinnetti C; Bacarelli A; Prosperi M; Fadda G; Cauda R; De Luca A Antivir Ther; 2007; 12(5):835-9. PubMed ID: 17713168 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]